Thrombolytic potency of acid-stabilized plasmin: Superiority over tissue-type plasminogen activator in an in vitro model of catheter-assisted thrombolysis

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 5, 2003, Pages 1034-1041

  Novokhatny, V ^a   Taylor, K ^a   Zimmerman, T P ^a  

^a BAYER CORPORATION   (United States)

Author keywords

Catheter; Peripheral arterial occlusion; Plasmin; Thrombolysis; Tissue plasminogen activator

Indexed keywords

EID: 0842282394     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00128.x     Document Type: Article

References (38)

1. Anderson RN. Deaths: Leading causes for 2000. National Vital Statistics Reports Vol. 50, No. 16; 1-86. Hyattsville, MD: National Center for Health Statistics, 2000.
2. Collen D. Thrombolytic therapy. Thromb Haemost 1997; 78: 742-6.
3. Marder V. Thrombolytic therapy. Blood Rev 2001; 15: 143-57.
4. Robbins KC, Summaria L. Plasminogen and plasmin. Methods Enzymol 1976; 45: 257-73.
5. Ponting CP, Marshall JM, Cederholm-Williams SA. Plasminogen: a structural review. Blood Coagulation Fibrinolysis 1992; 3: 605-14.
6. Sottrup-Jensen L, Claeys H, Zajdel M, Petersen TE, Magnusson S. The primary structure of human plasminogen. isolation of two lysine-binding fragments and one 'mini'-plasminogen (MW 38000) by elastase catalysed specific limited proteolysis. In: Davidson, JF, Rowan, RM, Samama, MM, Desnoyers, PC, eds. Progress in Chemical Fibrinolysis and Thrombolysis. New York: Raven Press, 1978: 191-209.
7. Lerch PG, Rickli EE, LergierW, Gillessen D. Localization of individual lysine-binding regions in human plasminogen and investigation on their complex-forming properties. Eur J Biochem 1980; 107: 7-13.
8. Lucas MA, Fretto LJ, McKee PA. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem 1983; 258: 4249-56.
9. Wu HL, Chang BI, Wu DH, Chang LC, Gong CC, Lou KL, Shi GY. Interaction of plasminogen and fibrin in plasminogen activation. J Biol Chem 1990; 265: 19658-64.
10. Wiman B, Lijnen HR, Collen D. On the specific interaction between the lysine binding sites in plasmin and complementary sites in a2-antiplasmin and in fibrinogen. Biochim Biophys Acta 1979; 579: 142-54.
11. Collen D. The plasminogen (fibrinolytic) system. Thromb Haemostas 1999; 82: 259-70.
12. Ouriel K. Thrombolytic therapy for acute arterial occlusion. J Am Coll Surg 2002; 194 (Suppl. 1): 32-9.
13. Schweizer J, KirchW, Koch R, Elix H, Hellner G, Forkmann L, Graf A. Short- and long-term results after thrombolytic treatment of deep venous thrombosis. J Am Coll Cardiol 2000; 36: 1336-43.
14. Hofling B, von Polnitz A. Invasive strategy for treatment of myocardial infarction. J Cardiovasc Pharmacol 1990; 16 (Suppl. 5): 120-2.
15. Ishibashi F, Saito T, Hokimoto S, Noda K, Moriyama Y, Oshima S. Combined revascularization strategy for acute myocardial infarction in patients with intracoronary thrombus: preceding intracoronary thrombolysis and subsequent mechanical angioplasty. Jpn Circ J 2001; 65: 251-6.
16. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999; 282: 2003-11.
17. Wechsler LR. Innovative strategies in the management of acute stroke. Curr Cardiol Rep 2002; 4: 135-40.
18. Ambrus JL, Ambrus CM, Back N, Sokal JE, Collins GL. Clinical and experimental studies on fibrinolytic enzymes. Ann N Y Acad Sci 1957; 68: 97-136.
19. Alkjaersig N, Fletcher AP, Sherry S. The mechanism of clot dissolution by plasmin. J Clin Invest 1959; 38: 1086-95.
20. Verstraete M, Vermilen J, Amery A. Enzymatic clot dissolution in man: a new therapeutic approach. Acta Clinica Belgica 1964; 19: 271-90.
21. Moser KM. Effect of intravenous administration of fibrinolysin (plasmin) in man. Circulation 1959; 20: 42-55.
22. Clifton EE. Review of clinical experience with clot-lysing agents. Am J Cardiol 1960; 6: 476-86.
23. Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095-6.
24. Marder VJ, Landskroner K, Novokhatny V, Zimmerman TP, Kong M, Kanouse JJ, Jesmok G. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost 2001; 86: 739-45.
25. Robbins KC, Summaria L. Human plasminogen and plasmin. Methods Enzymol 1970; 19: 257-73.
26. Hayes ML, Castellino FJ. Carbohydrate of the human plasminogen variant. I. Carbohydrate composition, glycopeptide isolation, and characterization. J Biol Chem 1979; 254: 8768-71.
27. Hayes ML, Castellino FJ. Carbohydrate of the human plasminogen variant. II. Structure of the asparagine-linked oligosaccharide unit. J Biol Chem 1979; 254: 8772-6.
28. Hayes ML, Castellino FJ. Carbohydrate of the human plasminogen variant. III. Structure of the O-glycosidally linked oligosaccharide unit. J Biol Chem 1979; 254: 8777-80.
29. Ouriel K, Kandarpa K, Schuerr DM, Hultquist M, Hodkinson G, Wallin B. Prourokinase versus urokinase for recanalization of peripheral occlusions, safety and efficacy: The PURPOSE trial. J Vasc Interv Radiol 1990; 10: 1083-91.
30. Sabovic M, Lijnen HR, Keber D, Collen D. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators. Thromb Haemost 1989; 62: 1083-78.
31. No authors. Thrombolysis in the management of lower limb peripheral arterial occlusion - a consensus document. Working Party on Thrombolysis in the Management of Limb Ischemia. Am J Cardiol 1998; 81: 207-18.
32. Gottlob R. Plasminogen and plasma inhibitors in arterial and venous thrombi of various ages. In: Davidson JF, Samama MM, Desnoyers PC, eds. Progress in Chemical Fibrinolysis and Thrombolysis. New York: Raven Press, 1975, 23-36.
33. Potter van Loon BJ, Rijken DC, Brommer EJP, van der Maas APC. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to exvivo lysibility. Thromb Haemost 1992; 67: 101-5.
34. Robbie LA, Bennett B, Croll AM, Brown PAJ, Booth NA. Proteins of the fibrinolytic system in human thrombi. Thromb Haemost 1996; 75: 127-33.
35. Barron HV, Rundle AC, Gore JM, Gurwitz JH, Penney J. Intracranial hemorrhage rates and effect of immediate beta-blocker use in patients with acute myocardial infarction treated with tissue plasminogen activator. Participants in the National Registry of Myocardial Infarction-2. Am J Cardiol 2000; 85: 294-8.
36. Ouriel K, Gray B, Clair DG, Olin J. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis. J Vasc Interv Radiol 2000; 11: 295-8.
37. Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 1978; 84: 573-8.
38. Collen D, Wiman B. Fast-acting plasmin inhibitor in human plasma. Blood 1978; 51: 563-9.